{"name":"Haisco Pharmaceutical Group Co., Ltd.","slug":"haisco-pharmaceutical-group-co-ltd","ticker":"","exchange":"","domain":"haisco.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"oncology","drugs":[{"name":"HSK39297 tablets","genericName":"HSK39297 tablets","slug":"hsk39297-tablets","indication":"Other","status":"phase_3"},{"name":"Daily DPP-4 inhibitor","genericName":"Daily DPP-4 inhibitor","slug":"daily-dpp-4-inhibitor","indication":"Other","status":"marketed"},{"name":"HL231 Solution for Inhalation","genericName":"HL231 Solution for Inhalation","slug":"hl231-solution-for-inhalation","indication":"Other","status":"phase_3"},{"name":"HSK21542 dose level 1","genericName":"HSK21542 dose level 1","slug":"hsk21542-dose-level-1","indication":"Other","status":"phase_2"},{"name":"HSK31858","genericName":"HSK31858","slug":"hsk31858","indication":"Other","status":"phase_2"},{"name":"HSK39297 100mgBID","genericName":"HSK39297 100mgBID","slug":"hsk39297-100mgbid","indication":"Other","status":"phase_2"},{"name":"HSK44459 dose level 1","genericName":"HSK44459 dose level 1","slug":"hsk44459-dose-level-1","indication":"Other","status":"phase_2"},{"name":"HSK47388","genericName":"HSK47388","slug":"hsk47388","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"HSK31858, tablet","genericName":"HSK31858, tablet","slug":"hsk31858-tablet","indication":"FGFR-driven solid tumors (phase 3 development)","status":"phase_3"},{"name":"HSK39297","genericName":"HSK39297","slug":"hsk39297","indication":"FGFR-driven solid tumors (Phase 3 development)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Acetyllevocarnitine Hydrochloride Tablets","genericName":"Acetyllevocarnitine Hydrochloride Tablets","slug":"acetyllevocarnitine-hydrochloride-tablets","indication":"Age-related cognitive decline","status":"phase_3"}]}],"pipeline":[{"name":"HSK39297 tablets","genericName":"HSK39297 tablets","slug":"hsk39297-tablets","phase":"phase_3","mechanism":"HSK39297 is an investigational small molecule that modulates specific cellular pathways to treat its target indication.","indications":[],"catalyst":""},{"name":"Acetyllevocarnitine Hydrochloride Tablets","genericName":"Acetyllevocarnitine Hydrochloride Tablets","slug":"acetyllevocarnitine-hydrochloride-tablets","phase":"phase_3","mechanism":"Acetyl-L-carnitine enhances cellular energy production by facilitating the transport of long-chain fatty acids into mitochondria for beta-oxidation.","indications":["Age-related cognitive decline","Peripheral neuropathy","Myasthenia gravis","Metabolic disorders associated with carnitine deficiency"],"catalyst":""},{"name":"Daily DPP-4 inhibitor","genericName":"Daily DPP-4 inhibitor","slug":"daily-dpp-4-inhibitor","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HL231 Solution for Inhalation","genericName":"HL231 Solution for Inhalation","slug":"hl231-solution-for-inhalation","phase":"phase_3","mechanism":"HL231 is an inhaled formulation designed to deliver therapeutic agents directly to the respiratory tract for local and/or systemic effects.","indications":[],"catalyst":""},{"name":"HSK21542 dose level 1","genericName":"HSK21542 dose level 1","slug":"hsk21542-dose-level-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HSK31858","genericName":"HSK31858","slug":"hsk31858","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HSK31858, tablet","genericName":"HSK31858, tablet","slug":"hsk31858-tablet","phase":"phase_3","mechanism":"HSK31858 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR-driven solid tumors (phase 3 development)"],"catalyst":""},{"name":"HSK39297","genericName":"HSK39297","slug":"hsk39297","phase":"phase_3","mechanism":"HSK39297 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR-driven solid tumors (Phase 3 development)"],"catalyst":""},{"name":"HSK39297 100mgBID","genericName":"HSK39297 100mgBID","slug":"hsk39297-100mgbid","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HSK44459 dose level 1","genericName":"HSK44459 dose level 1","slug":"hsk44459-dose-level-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HSK47388","genericName":"HSK47388","slug":"hsk47388","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNWE13UWg0d1UtcXpDY1BhTEwtNFUzU0pxWC1PcDgySUsxblBXai1aSkdrNmphaUtEQVRrVi04VzBGMUwwaG9YYVFiUGpoR0JFWTNaYldhWENyX3ZWRHJDSC1jdU5uM2FfN2Y3YkpHTVQ5VzVub2I1QUI3X3Frd3k3MndoU3k4eFIyNG5hT2JGNElYV1pMRzFyeU1kZmlhYlp0RG1IYmlIQkdmQmY4bjZ4UHkzaklVVTVETVVuZHlhQXJlUGRPWFVGeFRSa1dDVHdiOXV3cWJVenlUQWZpN3VFbk1RVXZPbFRzelNVZg?oc=5","date":"2026-04-02","type":"pipeline","source":"Barchart.com","summary":"Chronic and Acute Pain Treatment Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"Chronic and Acute Pain Treatment Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5CcnF5ZS1udWNoWDhJb29mU1VYZ0VGRDM4RVdYUFo0b1ZRUWRBY1diODFJUElUSlN2Mm9NZ0lGS3BUbzNyazhrOUZicG1nNm1Qb1NLUmpR?oc=5","date":"2026-03-10","type":"pipeline","source":"Forbes","summary":"Wang Junmin - Forbes","headline":"Wang Junmin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPbTQ4dFNtN3ZWMHZHY1NwMmgzbVZvVzF0VElQNWVWWXVHQ1BjTXIxTmQ4VWY4RGdfVlFVYkU0LVBPbHZJQThMQmRHRGFYc19yYXZOeFJVSjh2UFNoR2hfT0tHZmZYdmdpVDJlOWtnQklZSERqdWxidWtvVjJCLWQyMVladEh4b0hsZ0lXZGRkWXFsc1FLU1hjWkdDdmx3WmNSQ0FfT1FGcmIxejI3Rnk3LWpCbm8yNS0xQmUtVFRsajhtTHdrWkZ6S3gwNTNxd1cxTkE3RWZnS2t6V3FLY2FUN2JQbGRrVWlMY1kzRkdRcUVVMms3WUhPQnhCbkwzeWxsRnFva0oyVEVjdUx6ZTAycFBQakh0dXVSRENRb2hfTjBoNEtUOTZGdGtNem5nemJBaEQ0elRhT245eG9H?oc=5","date":"2026-01-28","type":"trial","source":"GlobeNewswire","summary":"Chronic and Acute Pain Clinical Trial Pipeline Analysis: - GlobeNewswire","headline":"Chronic and Acute Pain Clinical Trial Pipeline Analysis:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNRG12S3NpMEktUmxVUjBCdlhJRFljTjNZbUhFVkZWd05OcVVvTFFNTVdUSDNzTW1BMHQ3U3VjejB1bGlSYTAzQ3k4OFZSa1Q3dHBMbDB1LXRQZHh3Tjl1YVB6LV9hakhBM1BudWRKT3NIOUYtY0t2TUJoWFl4ZHgzUkdwb0g4U2xncEtJOEQ5OExrZVNWT051YTF0QTQwU3lFSFczNS1kZDhwZjZZdnUyRHR1YTU0UVBWZHRDbVJxcDRGU3N4SUxNNGs5Yk90V3JGbEhrRzc3dENOeVlDNC1NVEJWS3hOckZZUkYtaXRPX1RwdWRiTmZib21QcVpJYWM?oc=5","date":"2026-01-13","type":"deal","source":"Citeline News & Insights","summary":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","headline":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQdmlINXk4dF84aXhyMDFjT2pCYnRneGp2bVhFUWUwSjZ6alMzbkswVkx5QllEMDlEUXpvZEVNZ0JSVnFjc25lNW9Cc1lKbVdWV3FxdWg0Wnh0WTFELXUtS00xZE9qaGtoUG91NjY4Nk1sdU83TFdkSFQ0NFpTZFVqZmduM0VlN3JOeFM1TmUzMTNvZl9fTUtMeHFxUDhyVk9YOTlNcnQwQzJ4dFJybDczV28yMA?oc=5","date":"2026-01-09","type":"deal","source":"Fierce Biotech","summary":"AirNexis takes flight with $200M, links up with China pharma for COPD asset in $955M biobucks deal - Fierce Biotech","headline":"AirNexis takes flight with $200M, links up with China pharma for COPD asset in $955M biobucks deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPWEVNTkFJTmlfN2VzYzVoMnNneXdxOGRKUVoxbEplbnc0Y1BON2dyUDh5TnJ1RTZKaHRtV3NXeDRDcHA4VGc0RzNBMDNaNkd1eG5fM0lVcTYtS0tuTjJDX2FJUG1LbnpRelpUOVFVOFBDWWVtLU1UU0pudE0zM09wWXI1RGtnRzctUFBPb1dtWlpIdWlIMmJwdGZRc2szQVZjdmJJSU5tNlhsbzhleDNV?oc=5","date":"2023-11-20","type":"deal","source":"Contract Pharma","summary":"Chiesi, Haisco Partner on DPP1 Inhibitor for Respiratory Diseases - Contract Pharma","headline":"Chiesi, Haisco Partner on DPP1 Inhibitor for Respiratory Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNUDZFVGtHeElndzB4NHlxZDdpcHN1Q3U2U2hMY3RJU2JMUHoxWi1OdWxIcTJKMm5CWUdyZmRsWDlKREF1bEJzendkU2ZQa0kwOVFQVUpCV1VuNzA1UlpjbWoxWWhiZmNhbXEzTExiWkd2SGdxLW1KQV9CSlVUWXdQc1RPR3dfVjh1dnVrSm5wZ0kwWndsbGJwcQ?oc=5","date":"2019-04-03","type":"deal","source":"Yicai Global","summary":"Haisco Pharma Buys Into US New Drug Startup for USD6 Million - Yicai Global","headline":"Haisco Pharma Buys Into US New Drug Startup for USD6 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOTEROczgxTUVwSmhEV0NMSnFlWFIyYTZYMndnd0trd0NYNUhmd3F5bm5JS0lHa0kwOEExQnVJQzRCYzdYMDZQWV96SFhpdWdEZHEzZlVac3NiSTFqdV9UeTI0VzhaYTFqQ3F0TlRINWFJeXBuZTgxV0p3azBQcVFnaEliS0hxWjNDTk9pUFgzUUVQTzlCdXJET0dYbFhsUFJKZUx2SWR1MVZaX3g1QXlsU2YwZ2sxMDlKTGozRWZsQm9sejQ?oc=5","date":"2012-12-21","type":"pipeline","source":"NextInsight","summary":"FAN XIULIAN: Haisco Pharma Mogul Has Remedy For Riches - NextInsight","headline":"FAN XIULIAN: Haisco Pharma Mogul Has Remedy For Riches","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"phase_3":5,"marketed":1,"phase_2":5},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}